Compare GLDG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDG | STTK |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.1M | 275.9M |
| IPO Year | 2012 | 2020 |
| Metric | GLDG | STTK |
|---|---|---|
| Price | $1.14 | $6.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.50 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 2.4M | 676.2K |
| Earning Date | 04-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.69 |
| 52 Week High | $2.27 | $6.59 |
| Indicator | GLDG | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 78.49 |
| Support Level | $0.76 | $1.85 |
| Resistance Level | $1.31 | N/A |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 16.67 | 98.72 |
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. Its principal projects are the La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; the Sao Jorge Gold Project, located in Brazil; and its interest in the Whistler Gold-Copper Project, located in Alaska, United States. Additionally, the company has several other projects in its portfolio, such as the Yellowknife Gold Project, Cachoeira Gold Project, Surubim Gold Project, Yarumalito Gold Project, Rea Uranium Project, etc. The firm has two operating segments, with U.S. GoldMining as one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.